In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.
The in vitro cytotoxic effects of some recently synthesized copper (II) complexes were investigated in combination with two clinically important anticancer agents, cisplatin (CDDP) and epirubicin (EPR), on three human breast cancer cell lines (BT20, MCF7 and T47D), a human cervical carcinoma cell line (HeLa) and two non-tumour cell lines (BHK-21 and L929). The in vitro antiproliferative effects were measured by means of XTT assay and drug potency was expressed in terms of IC50 values. Synergistic effects were observed for EPR in combination with a Cu(II) malonate derivative in BT20, MCF7 and HeLa cells. Antagonistic effects were apparent when CDDP combined with a pivalate derivative in HeLa cells. For other drug combinations, synergism, adjuvance or antagonism was demonstrable depending on the cell line applied or the varied administration schedules. The results suggest that these novel complexes may enhance the cytotoxic activity of CDDP or EPR against human tumour cell lines when administered in combination with them.
Research Department, Theagenion Cancer Institute, Thessaloniki, Greece.
G D
GD
Geromichalos
G A
GA
Katsoulos
C C
CC
Hadjikostas
A H
AH
Kortsaris
D A
DA
Kyriakidis
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001943:Breast Neoplasms; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002945:Cisplatin / Q000008:administration & dosage; D003124:Colorimetry; D003300:Copper / Q000008:administration & dosage / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006367:HeLa Cells; D006801:Humans; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms
D015251:Epirubicin; D003300:Copper; D002945:Cisplatin